Bora Pharmaceuticals continues to expand into the global CDMO market with the acquisition of Eden Biologics

Update : 13th May, 2022

Bora Pharmaceuticals, a Taiwan-based CDMO, Consumer Healthcare, OTC, and Prescription Drug manufacturer, have announced their acquisition of Eden Biologics. Eden Biologics, also Taiwan-based, provides CDMO services for developing biosimilars. Bora Pharmaceuticals, established in 2007, has grown consistently, adding operations at home in Taiwan, in North America, and, more recently, in 2020, acquiring GlaxoSmithKline’s Mississauga, Ontario facility.

Simon Chen, Bora Vice President, commented, “The addition of the CDMO facilities state of the art equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialization.”

As part of their global company growth plan, Bora plans to invest up to USD 100 million in Eden Biologics’ CDMO assets in Taiwan. Eden Biologics’ facility has four 500L bioreactors, certified by EU Qualified Person (QP) and the Taiwan Food and Drug Administration, Ministry of Health and Welfare.

Source : Bora Pharmaceuticals


This news article complies with our Editorial Policy

Other News

Follow CCP